Table 3.
Drugs targeting histone modifications in uterine sarcoma cells.
| Drugs/Factors | Epigenetic Targets | Biological Samples | Effectors | Biological Effect | Approach | Publication Time | Refs. |
|---|---|---|---|---|---|---|---|
| Vorinostat | HDACs | MES-SA | p21 | apoptosis, tumor growth inhibition | in vitro and in vivo | 2010 | [131] |
| Valproic acid | HDACs | MES-SA | NA | cytotoxic effect | in vitro | 2013 | [130] |
| SAHA, LY294002, rapamycin | HDACs | MES-SA | AKT, mTOR/p70S6K | growth inhibition | in vitro | 2014 | [104] |
| FASN | H3K9me3, H3K27ac | SK-UT-1 | CRISP1 | proliferation, migration, cellular motion | in vitro | 2017 | [227] |
| GS-626510 | BET bromodomain | uLMS PDX model | NA | tumor growth inhibition | in vivo | 2021 | [59] |
| Tucidinostat, sulforaphane | HDACs | SK-UT-1 | PCNA, CDK members | cell proliferation, | in vitro | 2022 | [126] |
| TP-472 | BRD9 | SK-UT-1 | H3K4me3, YTHDC1, YTHDF2 | cell cycle, cell proliferation, apoptosis | in vitro | 2022 | [142] |
Note: LY294002: inhibitor of PI3K; rapamycin: mammalian target of rapamycin mTOR; FASN: fatty acid synthase; NA: not available; LM: leiomyoma.